Severe acute respiratory syndrome

Nature Medicine

Volumn 10, Issue 12S, 2004, Pages S88-S97

  Peiris, J S M ^a   Guan, Y ^a   Yuen, K Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CONSENSUS INTERFERON; DNA VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; INACTIVATED VIRUS VACCINE; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; NELFINAVIR; NUCLEOCAPSID PROTEIN; PROTEINASE INHIBITOR; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ANTIBODY; VIRUS RECEPTOR; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANTIGENIC VARIATION; ARTIFICIAL VENTILATION; CHINA; CLINICAL FEATURE; DRUG TARGETING; ELECTRON MICROSCOPY; EPIDEMIC; EPIDEMIOLOGICAL DATA; GENE DELETION; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFECTION CONTROL; INTENSIVE CARE; LYMPHOCYTOPENIA; MOLECULAR PHYLOGENY; NONHUMAN; OPEN READING FRAME; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION, PASSIVE; MODELS, BIOLOGICAL; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION; WORLD HEALTH; ZOONOSES;

ANIMALIA; CORONAVIRUS; RNA VIRUSES; SARS CORONAVIRUS;

EID: 10944238037     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1143     Document Type: Review

References (149)

1. Smith, M.D. Plague. in Manson’s Tropical Diseases 21st edn (eds Cook, G.C. ä Zumla, A.) Ch. 63, 1125-1131 (W. B. Saunders, London, 2003).
2. Shortridge, K.F. à Stuart-Harris, C.H. An influenza epicentre? Lancet2, 812-813 (1982).
3. Centers for Disease Control and Prevention. Update: Outbreak of severe acute respiratory syndrome-worldwide, 2003. Morbid. Mortal. Wkly. Rpt. 52, 241-248 (2003).
4. Tsang, K.W. et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1977-1985 (2003).
5. Lee, N. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348, 1986-1994 (2003).
6. Poutanen, S.M. et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348, 1995-2005 (2003).
7. Peiris, J.S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003).
8. Ksiazek, T.G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
9. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003).
10. Poon, L.L. et al. Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS). Clin. Chem. 49, 953-955 (2003).
11. Marra, M.A. et al. The genome sequence of the SARS associated coronavirus. Science 300, 1399-1404 (2003).
12. Rota, P.A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394-1399 (2003).
13. Enserink, M. One year after outbreak. SARS virus yields some secrets. Science 304, 1097 (2004).
14. Peiris, J.S.M., Yuen, K.Y., Osterhaus, A.D.M.E. à Stohr, K. The severe acute respiratory syndrome. N. Engl. J. Med. 349, 2431-2441 (2003).
15. Christian, M.D., Poutanen, S.M., Loufty, M.R., Muller, M.P. à Low, D.E. Severe acute respiratory syndrome. Clin. Infect. Dis. 38, 1420-1427 (2004).
16. Rainer, T.H. Severe acute respiratory syndrome: Clinical features, diagnosis and management. Curr. Opin. Pulm. Med. 10, 159-165 (2004).
17. Drosten, C., Preiser, W., Gunther, S., Schmitz, H. à Doerr, H.W. Severe acute respiratory syndrome: Identification of the aetiologic agent. Trends Mol. Med. 9, 325-327 (2003).
18. Holmes, K.V. SARS coronavirus: A new challenge for prevention and therapy. J. Clin. Invest. 111, 1605-1609 (2003).
19. Davidson, A. à Siddell, S. Potential for antiviral treatment of severe acute respiratory syndrome. Curr. Opin. Infect. Dis. 26, 565-571 (2003).
20. Stadler, K. et al. SARS-beginning to understand a new virus. Nat. Rev. Microbiol. 1, 209-218 (2003).
21. Poon, L.L.M., Guan, Y., Nicholls, N.J., Yuen, K.Y. à Peiris, J.S.M. The aetiology, origins and diagnosis of SARS. Lancet Infect. Dis. 4, 663-671 (2004).
22. Anderson, R.M. et al. Epidemiology, transmission dynamics, and control of SARS. The 2002-2003 epidemic. Phil. Trans. R. Soc. Lond. B359, 1091-1105 (2004).
23. Poutanen, S.M. à Low, D.E. Severe acute respiratory syndrome: An update. Curr. Opin. Infect. Dis. 17, 287-294 (2004)
24. Poutanen, S.M. à McGeer, A.J. Transmission and control of severe acute respiratory syndrome. Curr. Infect. Dis. Rep. 6, 220-227 (2004)
25. Weinstein, R.A. Planning for epidemics-the lessons of SARS. N. Engl. J. Med. 350, 2332-2334 (2004).
26. Zhong, N.S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February 2003. Lancet 362, 1355-1358 (2003).
27. Xu, R.H. et al. Epidemiologic clues to SARS origin in China. Emerg. Infect. Dis. 10, 1030-1037 (2004).
28. Zhong, N.S. à Zeng, G.Q. Our strategies for fighting severe acute respiratory syndrome (SARS). Am. J. Respir. Crit. Care Med. 168, 7-9 (2003).
29. Guan, Y. et al. Isolation and characterization of viruses related to SARS coronavirus from animals in southern China. Science 302, 276-278 (2003).
30. Centers for Disease Control and Prevention. Prevalence of IgG antibody to SARS- associated coronavirus in animal traders-Guangdong Province, China, 2003. Morb. Mortal. Wkly. Rep. 52, 986-987 (2003).
31. Klempner, M.S. & Shapiro, D.S. Crossing the species barrier-one small step to man, one giant leap to mankind. N. Engl. J. Med. 350, 1171-1172 (2004).
32. Snijder, E.J. et al. Unique and conserved features of genomes and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 33, 991-1004 (2003).
33. Gorbalenya, A.E., Snijder, A.E. & Spaan, W.J. Severe acute respiratory syndrome coronavirus phylogeny: Toward consensus. J. Virol. 78, 7863-7866 (2004).
34. The Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303, 1666-1669 (2004).
35. Guan, Y. et al. Molecular epidemiology of SARS coronavirus in Hong Kong. Lancet 363, 99-104 (2004).
36. Ruan, Y. et al. Comparative full-length genome sequence analysis of 14 SARS coro- navirus isolates and common mutations associated with putative origins of infection. Lancet361, 1779-1785 (2003).
37. Yeh, S.H. et al. Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution. Proc. Natl. Acad. Sci. USA 101, 2542-2547 (2004).
38. Zhong, N. Management and prevention of SARS in China. Phil. Trans. R. Soc. Lond. B. 359, 1115-1116 (2004).
39. Liang, G. et al. Laboratory diagnosis of four recent sporadic cases of community- acquired SARS, Guangdong Province, China. Emerg. Infect. Dis. 10, 1774-1781 (2004).
40. Wong, T.W. et al. Cluster of SARS among medical students exposed to single patient, Hong Kong. Emerg. Infect. Dis. 10, 269-276 (2004).
41. Seto, W.H., et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 361, 1519-1520 (2003).
42. Loon, S.C. et al. The severe acute respiratory syndrome coronavirus in tears. Br. J. Ophthalmol. 88, 861-863 (2004).
43. Leung, G.M. et al. SARS CoV antibody prevalence in all Hong Kong patient contacts. Emerg. Infect. Dis. 10, 1653-1656 (2004)
44. Lipsitch, M. et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 300, 1966-1970 (2003).
45. Goh, D.L.M. et al. Secondary household transmission of SARS, Singapore. Emerg. Infect. Dis. 10, 232-234 (2004).
46. Shen, Z. et al. Super-spreading SARS events in Beijing, 2003. Emerg. Infect. Dis. 10, 256-260 (2004).
47. Peiris, J.S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 361, 1767-1772 (2003).
48. Chan, K.H. et al. Detection of SARS coronavirus (SCoV) by RT-PCR, culture, and serology in patients with acute respiratory syndrome (SARS). Emerg. Infect. Dis. 10, 294-299 (2004).
49. Chan, P.K. et al. Laboratory diagnosis of SARS. Emerg. Infect. Dis. 10, 825-830 (2004).
50. Li, L. et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. J. Clin. Virol. 28, 239-244 (2003).
51. Ng, E.K. et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin. Chem. 49, 2085-2088 (2003).
52. Wong, R.S.M. et al. Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. BMJ326, 1358-1362 (2003).
53. Li, T. et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis. 189, 648-651 (2004).
54. Leung, C.W. et al. Severe acute respiratory syndrome in children. Pediatrics 113, e535-e543 (2004).
55. Hon, K.L. et al. Clinical presentation and outcome of severe acute respiratory syndrome in children. Lancet361, 1701-1703 (2003).
56. Drosten, C. et al. Evaluation of advanced reverse transcription PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome- associated coronavirus. J. Clin. Microbiol. 42, 2043-2047 (2004).
57. Cheng, P.K.C. et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet363, 1699-1700 (2004).
58. Kaiser, L., Briones, M.S. & Hayden, F.G. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J. Clin. Virol. 14, 191-197 (1999).
59. Ng, E.K. et al. Quantitation analysis and prognostic implication of SARS coron- avirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin. Chem. 49, 1976-1980 (2003).
60. Hung, I.F. et al. Viral loads in clinical specimens and SARS manifestations. Emerg. Infect. Dis. 10, 1550-1557 (2004).
61. Chu, C.M. et al. The role of lopinavir/ritonavir in treatment of SARS: Initial virologi- cal and clinical findings. Thorax 59, 252-256 (2004).
62. Mazzulli, T. et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg. Infect. Dis. 10, 20-24 (2003).
63. Nicholls, J.M. et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361, 1773-1778 (2003).
64. Franks, T.J. et al. Lung pathology of severe acute respiratory syndrome (SARS): A
65. study of 8 autopsy cases from Singapore. Hum. Pathol. 34, 743-748 (2003).
66. Chow, K.C. et al. Detection of severe acute respiratory syndrome-associated coron- avirus in pneumocytes of the lung. Am. J. Clin. Pathol. 121, 574-580 (2004).
67. To, K.F. et al. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: An in situ hybridization study of fatal cases. J. Pathol. 202, 157-163 (2004).
68. Nakajima, N. et al. SARS Coronavirus-infected cells in lung detected by new in situ hybridization technique. Jpn. J. Infect. Dis. 56, 139-141 (2003).
69. Chong, P.Y. et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore. Arch. Pathol. Lab. Med. 128, 195-204 (2004).
70. Ding, Y. et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways. J. Pathol. 203, 622-630 (2004).
71. To, K.F. & Lo, A.W.I. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): The tissue distribution of the coronavirus (SARS CoV) and its putative receptor, angiotensin-converting-enzyme 2 (ACE-2). J. Pathol. 203, 740-743 (2004).
72. Leung, W.K. et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 125, 1011-1017 (2003).
73. Chan, P.K.S. et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J. Med. Virol. 74, 1-7 (2004).
74. Cinatl, J. et al. Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus. Cell Mol. Life Sci. 61, 2100-2112 (2004).
75. Yang, Z.Y. et al. pH-dependent entry of severe acute respiratory syndrome coron- avirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC SIGN. J. Virol. 78, 5642-5650 (2004).
76. Simmons, G. et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. USA101, 4240-4245 (2004).
77. Hoffmann, H. et al. Susceptibility to SARS coronavirus S protein-derived infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem. Biophys. Res. Comm. 319, 1216-1221 (2004).
78. Han, D.P., Kim, H.G., Kim, Y.B., Poon L.L.M. & Cho, M.W. Development of a safe neutralization assay for SARS CoV and characterization of S-glycoprotein. Virology 326, 140-149 (2004).
79. Bosch, B.J. et al. Severe acute respiratory syndrome associated coronavirus (SARS CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. USA101, 8455-8460 (2004).
80. Liu, S. et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechnism and identification of fusion inhibitors. Lancet 363, 938-947 (2004).
81. Qinfen, Z., et al. The life cycle of SARS coronavirus in Vero E6 cells. J. Med. Virol. 73, 332-337 (2004).
82. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454 (2003).
83. Wang, P. et al. Expression cloning of functional receptor used by SARS coronavirus. Biochem. Biophys. Res. Commun. 315, 439-444 (2004).
84. Babcock, G.J., Esshaki, D.J., Thomas, W.D. & Ambrosino, D.M. Amino acids 270 to 510 of the severe acute respiratory syndrome spike protein are required for interaction with receptor. J. Virol. 78, 4552-4560 (2004).
85. Lai, M.M.C. & Holmes, K.V. Coronaviridae and their replication. in Fields’ Virology Vol2. (eds Knipe, D.M. & Howley, P.M) Ch. 35, 1163-1185 (Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2001).
86. Hammling, I. et al. Tissue distribution of ACE-2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631-637 (2004).
87. Yount, B. et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 100, 12995-13000 (2003).
88. Wong, C.K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136, 95-103 (2004).
89. Zhang, Y. et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect. Immun. 72, 4410-4415 (2004).
90. Ng, P.C. et al. Inflammatory cytokine profile in children with severe acute respiratory syndrome. Pediatrics 113, e7-e14 (2004).
91. Lee, C.H. et al. Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome. J. Immunol. 172, 7841-7847 (2004).
92. Peiris, J.S.M. et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363, 617-619 (2004).
93. Jones, B.M. et al. Prolonged disturbance of in vitro cytokine production inpatients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids. Clin. Exp. Immunol. 135, 467-473 (2004).
94. Openshaw, P.J.M. What does the peripheral blood tell you in SARS? Clin. Exp. Immunol. 136, 11-12 (2004).
95. Lin, M. et al. Association of HLA class 1 with severe acute respiratory syndrome coronavirus infection. BMC Med. Genet. 4, 9 (2003).
96. Ng, M.H.L. et al. Association of human-leukocyte-antigen class 1 (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J. Infect. Dis. 190, 5151-5158 (2004).
97. Fouchier, R.A.M. et al. Koch’s postulates fulfilled for SARS virus. Nature 423, 240 (2003).
98. Kuiken, T. et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263-270 (2003).
99. Rowe, T. et al. Macaque model for severe acute respiratory syndrome. J. Virol. 78, 11410-11414 (2004).
100. Martina, B.E. et al. Virology: SARS virus infection of cats and ferrets. Nature 425, 915 (2003).
101. Bukreyev, A. et al. Mucosal immunisation of African green monkeys (Cercopithicus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 2122-2127 (2004).
102. Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 78, 3572-3577 (2004).
103. Buchholtz, U.J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA 101, 9804-9809 (2004).
104. Roberts, A. et al. SARS coronavirus infection in Golden Syrian hamsters. J. Virol. (in the press).
105. Wu, C.Y. et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc. Natl. Acad. Sci. USA 101, 10012-10017 (2004).
106. Wu, C.J. et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother. 48, 2693-2696 (2004)
107. Chen, F. et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 31, 69-75 (2004).
108. Yi, Y. et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J. Virol. 78, 11334-11339 (2004).
109. Yamamoto, N. et al. HIV protease inhibitor nelfinavir inhibits replication of SARS- associated coronavirus. Biochem. Biophys. Res. Commun. 318, 719-725 (2004).
110. Tan, E.L. et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10, 581-586 (2004).
111. Hensley, L.E. et al. Interferon-ß 1a and SARS coronavirus replication. Emerg. Infect. Dis. 10, 317-319 (2004).
112. Stroher, U. et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-a. J. Infect. Dis. 189, 1164-1167 (2004).
113. Spiegel, M., Pichlmair, A., Muhlberger, E., Haller O. & Weber, F. The antiviral effect of interferon-ß against SARS coronavirus is not mediated by MxA protein. J. Clin. Virol. 30, 211-213 (2004).
114. Zhang, X.W. & Yap, Y.L. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic, and parasitic drugs. Bioorg. Med. Chem. 12, 2517-2521 (2004).
115. Haagmans, B.L. et al. Pegylated interferon-a protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10, 290-293 (2004).
116. Loutfy, M.R. et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. J. Am. Med. Assoc.290, 3222-3228 (2003).
117. Anand, K. et al. Coronavirus main protease (3Clpro) structure: Basis for design of antiviral drugs. Science300, 1763-1767 (2003).
118. Ivanov, K.A. et al. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J. Virol. 78, 5619-5632 (2004).
119. He, M.L. et al. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 290, 2665-2666 (2003).
120. Wang, Z. et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNA in mammalian cells. J. Virol. 78, 7523-7527 (2004).
121. Zhang, Y. et al. Silencing SARS CoV spike protein expression in cultured cells by RNA interference. FEBS Lett. 560, 141-146 (2004).
122. Kao, R.Y. et al. Identification of novel small molecule inhibitors of severe acute respiratory syndrome associated coronavirus by chemical genetics. Chem. Biol. 11, 1293-1299 (2004).
123. Lu, L. et al. Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 42, 1570-1576 (2004).
124. Zhang, H. et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike protein capable of inducing neutralizing antibodies. J. Virol. 78, 6938-6945 (2004).
125. Wang, Y.D. et al. T cell epitopes in severe acute respiratory syndrome (SARS) coro- navirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J. Virol. 78, 5612-5618 (2004).
126. Nie, Y. et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 190, 1119-1126 (2004).
127. Yang, Z.Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561-564 (2004).
128. Kim, T.W. et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 78, 4638-4645 (2004).
129. Zeng, F. et al. Characterization of humoral responses in mice immunized with plas- mid DNAs encoding SARS-CoV spike gene fragments. Biochem. Biophys. Res. Commun. 315, 1134-1139 (2004).
130. Zhu, M.S. et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett. 92, 237-243 (2004).
131. Gao, W. et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362, 1895-1896 (2003).
132. Bisht, H. et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA101, 6641-6646 (2004).
133. Takasuka, N. et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol. 16, 1423-1430 (2004).
134. Tang, L. et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 23, 391-394 (2004).
135. Cavanagh, D. Severe acute respiratory syndrome vaccine development: Experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 32, 567-582 (2003).
136. Olsen, C.W. A review of feline infectious peritonitis virus: Molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet. Microbiol. 36, 1-37 (1993).
137. Sui, J. et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAB to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA101, 2536-2641 (2004).
138. ter Muelen, J. et al. Human monoclonal antibody as prophylaxis for SARS coron- avirus infection in ferrets. Lancet 363, 2139-2141 (2004).
139. Traggian, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat. Med. 10, 871-875 (2004).
140. Soo, Y.O.Y. et al. Retrospective comparison of convalescent plasma with continuing high dose methyl prednisolone treatment in SARS patients. Clin. Microbiol. Infect.
141. 10, 657-658 (2004)
142. Smolinski, M.S., Hamburg, M.A. & Lederberg, J. (eds). Microbial Threats to Health: Emergence, Detection and Response (National Academy Press, Washington, DC, 2003).
143. Li, K.S. et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430, 209-213 (2004).
144. Mackenzie, J.S., Field, H.F. & Guyatt, K.J. Managing emerging diseases borne by fruit bats (flying foxes), with particular reference to henipaviruses and Australian bat lyssavirus. J. Appl. Microbiol. 94 Suppl, 59S-69S (2003).
145. Poon, L.L.M. et al. Identification of a novel coronavirus in bats. J. Virol. (in the press).
146. Singer, P.A. et al. Ethics and SARS: Lessons from Toronto. BMJ 327, 1342-1344 (2003).
147. O’Neill, O. Informed consent and public health. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 1133-1136 (2004)
148. World Health Organization. A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet 361, 1730-1733 (2003).
149. Fidler, D.P. Germs, governance, and global public health in the wake of SARS. J. Clin. Invest. 113, 799-804 (2004).